Re-Vana Therapeutics
Re-Vana Therapeutics develops proprietary photo-crosslinked, biodegradable ocular implants (EyeLief® and OcuLief®) that deliver biologics and small molecules over 3–12 months, licensing the platform to large pharmaceutical partners such as Boehringer Ingelheim to address chronic retinal diseases.
- Company typePrivate
- Founded2016
- HeadquartersBelfast, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Re-Vana Therapeutics does
Re-Vana Therapeutics is an ocular drug delivery company developing proprietary photo-crosslinked, biodegradable hydrogel implants for sustained-release therapeutics to the eye. Founded in 2016 as a spin-out from Queen's University Belfast, with a US subsidiary in Tampa, Florida, the company operates a dual-platform technology: EyeLief®, a pre-fabricated implant administered via narrow-gauge needle for low-release-rate sustained delivery (≤2 µg/day over ~6 months), and OcuLief®, an in situ photo-crosslinked liquid-to-solid system delivered through a 25G needle and cured via visible (405 nm) light, suited to higher-release-rate biologics (≥2 µg/day over 3–12 months). Both platforms are engineered to deliver biologics, peptides, and small/large molecules with zero-order kinetics, with API loading capacity up to 50% of implant weight and enhanced protein stability enabled by room-temperature manufacture and minimal pH shift.
Re-Vana serves large global pharmaceutical companies seeking long-acting ocular delivery solutions for retinal diseases (wet AMD, diabetic retinopathy, glaucoma) and operates a B2B technology-licensing model: partners lead clinical development, regulatory approval, and commercialization while Re-Vana continues formulation and preclinical development from Belfast. Revenue derives from upfront fees, development and regulatory milestones, commercial milestones, and royalties on net sales. The flagship commercial validation is a July 2025 strategic collaboration and license agreement with Boehringer Ingelheim — potential total deal value exceeding $1 billion across initial three targets plus royalties, with Boehringer retaining the right to nominate up to three new development projects per year. Re-Vana also maintains an earlier-stage research collaboration with Nicox.
The company is venture-backed (approximately $18 million raised to date across a 2020 pre-Series A of $3.25M and a 2022 Series A of $11.9M led by Visionary Ventures), is raising a $40 million Series B to advance an internal sustained-release anti-VEGF asset, and expanded into an 8,000 sq. ft. facility at Belfast's Catalyst Innovation Centre in March 2026. Leadership is concentrated in experienced drug delivery executives, including CEO Michael O'Rourke (former Bausch + Lomb Pharmaceuticals General Manager with Vitrasert®/Retisert® launch experience) and COO Patrick Ruane, with CBO Hans Christinger leading business development and transactional activity.
Re-Vana Therapeutics firmographics
Firmographics- Name
- Re-Vana Therapeutics
- Legal name
- Re-Vana Therapeutics Ltd
- Website
- https://revanatx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Re-Vana Therapeutics develops proprietary photo-crosslinked, biodegradable ocular implants (EyeLief® and OcuLief®) that deliver biologics and small molecules over 3–12 months, licensing the platform to large pharmaceutical partners such as Boehringer Ingelheim to address chronic retinal diseases.
- Ownership category
- akta.pro rank
Re-Vana Therapeutics industry classification
Industry- Product category
- Ocular Drug Delivery Systems
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Ophthalmic Goods (3851), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ophthalmology Pharmaceuticals (HLAIAAAL), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Re-Vana Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Belfast
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Re-Vana Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Licensing and Milestone Payments: Re-Vana receives upfront payments, development milestone payments, regulatory milestone payments, and commercial milestone payments from pharmaceutical partners. The Boehringer Ingelheim collaboration includes total potential deal value exceeding $1 billion for initial three targets, in addition to royalty payments on net sales.
- Strategic Collaboration Revenue: Revenue from co-development partnerships where Boehringer Ingelheim leads clinical development, regulatory approval, and global commercialization while Re-Vana continues development work from Belfast base.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Re-Vana Therapeutics product offering
Product offeringCore offering
Re-Vana Therapeutics develops proprietary photo-crosslinked, biodegradable ocular drug delivery platforms (EyeLief® pre-fabricated implants and OcuLief® in situ forming implants) that deliver biologics, peptides, and large and small molecules over 3-12 months via intravitreal injection. The company licenses these drug delivery technologies to global pharmaceutical partners such as Boehringer Ingelheim, who lead clinical development, regulatory approval, and commercialization in exchange for upfront, milestone, and royalty payments.
Product overview
Re-Vana Therapeutics offers a platform of proprietary photo-crosslinked, biodegradable ocular drug delivery technologies centered on two core product families: EyeLief® (pre-fabricated implants) and OcuLief® (in situ forming implants). Both platforms use light-based crosslinking to create sustained-release implants that deliver biologics, peptides, and small/large molecules over 3-12 months, reducing the need for frequent intravitreal injections in treating retinal diseases. EyeLief-SD™ represents an additional variant within the portfolio. The technology can be customized to achieve zero-order kinetics release of biologics and supports drug loading up to 50% of implant weight.
Differentiator
Problem solved
Functional benefit
Brands
- EyeLief: Photo-crosslinked, pre-fabricated implant technology administered via narrow-gauge needle for sustained release of biologics, peptides, and small molecules over 3-12 months.
- OcuLief
- EyeLief-SD
Products and services
- EyeLief® Patented photo-crosslinked, pre-fabricated intravitreal implant administered via narrow-gauge needles, engineered for sustained release of biologics, peptides, and small/large molecules over 3-12 months. Can carry up to 50% of its weight in active pharmaceutical ingredients and is customized via dimension, crosslink density, and drug loading for release rates of ≤2 µg/day over 6 months. Licensed to pharmaceutical partners for use in retinal disease programs.
- OcuLief® In situ photo-crosslinked intravitreal implant system delivered as a liquid through a 25G needle with a bespoke applicator, forming implants of up to 60mg upon exposure to visible light (405 nm). Suitable for biologics, peptides, and molecules requiring higher release rates of ≥2 µg/day for 3-12 months. Designed for in-clinic administration.
- EyeLief-SD™ Sustained delivery variant of the EyeLief biodegradable drug delivery technology platform for ocular therapeutics.
Quantifiable outcome
- Reduces injection frequency from every 4-6 weeks to once every 6-12 months
- +2 more outcomes
Companies that use Re-Vana Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
Re-Vana Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Re-Vana Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and minor.
- Boehringer IngelheimflagshipStrategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases. Boehringer Ingelheim can nominate up to three new development projects per year with potential total deal value exceeding $1 billion for initial three targets, plus royalty payments on net sales. Boehringer leads clinical development, regulatory approval, and global commercialization while Re-Vana continues development from Belfast.
- NicoxminorResearch collaboration agreement signed in October 2017 for feasibility studies on delivering proprietary therapeutics using Re-Vana's photo-crosslinked drug delivery systems.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Re-Vana Therapeutics competitors and assessment
Company assessmentDirect peers
- EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery technologies including the Durasert® platform for intravitreal delivery of corticosteroids and anti-VEGF agents. Direct competitor to Re-Vana's EyeLief®/OcuLief® platforms in the same target indications (wet AMD, diabetic retinopathy).
- Ocular Therapeutix: Ocular Therapeutix develops biodegradable hydrogel-based drug delivery systems for ophthalmic indications including sustained-release anti-VEGF therapies. Their technology platform and target indications closely overlap with Re-Vana's EyeLief® approach.
- Clearside Biomedical: Clearside Biomedical developed the suprachoroidal Microinjector® for delivering corticosteroids and gene therapies to the posterior segment of the eye. Targets similar retinal disease space using a novel administration route comparable in innovation approach to Re-Vana's photo-crosslinked delivery.
- Kodiak Sciences: Kodiak Sciences develops novel biologics-based therapies for retinal diseases including wet AMD and diabetic retinopathy. Competes in the same therapeutic indications that Re-Vana's delivery platform targets.
- GrayBug Vision: GrayBug Vision (acquired by Catalent) developed sustained-release ocular drug delivery technologies for wet AMD and glaucoma, with platforms aimed at extending dosing intervals. The CEO of Re-Vana previously served as CEO of GrayBug, indicating a closely comparable technology and commercial approach.
- Nicox: Nicox is a French ophthalmology company developing therapeutics for ocular conditions including retinal diseases. Re-Vana previously signed a 2017 research collaboration with Nicox to evaluate Re-Vana's photo-crosslinked delivery systems with Nicox's proprietary therapeutics.
Broad incumbents
- Genentech (Roche): Genentech developed Susvimo, the FDA-approved port delivery system for ranibizumab providing sustained ocular anti-VEGF delivery. As a major pharma incumbent with established ophthalmology franchise (Lucentis, Vabysmo), it competes broadly with Re-Vana's value proposition of reducing anti-VEGF injection burden.
- Santen Pharmaceutical: Santen is a major Japanese ophthalmology-focused pharmaceutical company with a broad portfolio of ocular therapeutics including products for retinal diseases and glaucoma. As a global incumbent in ophthalmology it represents the kind of partner/customer Re-Vana could engage for additional licensing deals.
Others
- Boehringer Ingelheim: Boehringer Ingelheim is Re-Vana's flagship strategic partner under the July 2025 collaboration and is developing extended-release ocular therapies using Re-Vana's photo-crosslinked platform. As a partner-customer, Boehringer Ingelheim shapes Re-Vana's commercial trajectory.
Emerging players
- Annexon, Inc. Annexon is a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases and other ophthalmology indications. While primarily a therapeutics developer rather than a delivery platform company, it overlaps in the same ophthalmology indication space that Re-Vana's delivery technology addresses.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Re-Vana Therapeutics social profiles
Digital presenceRe-Vana Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Re-Vana Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Re-Vana Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Re-Vana Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Re-Vana Therapeutics
What does Re-Vana Therapeutics do?
Re-Vana Therapeutics develops proprietary photo-crosslinked, biodegradable ocular drug delivery platforms (EyeLief® pre-fabricated implants and OcuLief® in situ forming implants) that deliver biologics, peptides, and large and small molecules over 3-12 months via intravitreal injection. The company licenses these drug delivery technologies to global pharmaceutical partners such as Boehringer Ingelheim, who lead clinical development, regulatory approval, and commercialization in exchange for upfront, milestone, and royalty payments.
Is Re-Vana Therapeutics a public or private company?
Re-Vana Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Re-Vana Therapeutics founded?
Re-Vana Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Re-Vana Therapeutics based?
Re-Vana Therapeutics is headquartered in Belfast, United Kingdom, in the Europe region.
How does Re-Vana Therapeutics make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are strategic Collaboration Revenue.
Who are Re-Vana Therapeutics's main competitors?
Direct peers on record are EyePoint Pharmaceuticals, Ocular Therapeutix, Clearside Biomedical, Kodiak Sciences, GrayBug Vision and Nicox. Broad incumbents are Genentech (Roche) and Santen Pharmaceutical. Boehringer Ingelheim is listed as an others. Annexon, Inc. is listed as an emerging player.
Does Re-Vana Therapeutics have an API?
No public API is recorded for Re-Vana Therapeutics.
What industry is Re-Vana Therapeutics in?
Re-Vana Therapeutics's product category is Ocular Drug Delivery Systems. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 3851.